BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38797108)

  • 1. Mechanisms associated with cuproptosis and implications for ovarian cancer.
    Chen B; Liu J
    J Inorg Biochem; 2024 Aug; 257():112578. PubMed ID: 38797108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper-mediated novel cell death pathway in tumor cells and implications for innovative cancer therapies.
    Zhang X; Tao T; Qiu Y; Guo X; Zhu X; Zhou X
    Biomed Pharmacother; 2023 Dec; 168():115730. PubMed ID: 37864891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cope with copper: From molecular mechanisms of cuproptosis to copper-related kidney diseases.
    Zou Y; Wu S; Xu X; Tan X; Yang S; Chen T; Zhang J; Li S; Li W; Wang F
    Int Immunopharmacol; 2024 May; 133():112075. PubMed ID: 38663316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging insights into cuproptosis and copper metabolism: implications for age-related diseases and potential therapeutic strategies.
    Fan H; Wang K; Zhao X; Song B; Yao T; Liu T; Gao G; Lu W; Liu C
    Front Aging Neurosci; 2024; 16():1335122. PubMed ID: 38715962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis in lung cancer: therapeutic options and prognostic models.
    Jawed R; Bhatti H
    Apoptosis; 2024 May; ():. PubMed ID: 38735011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Copper homeostasis and cuproptosis in cancer immunity and therapy.
    Liu WQ; Lin WR; Yan L; Xu WH; Yang J
    Immunol Rev; 2024 Jan; 321(1):211-227. PubMed ID: 37715546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cuproptosis: unveiling a new frontier in cancer biology and therapeutics.
    Feng Y; Yang Z; Wang J; Zhao H
    Cell Commun Signal; 2024 May; 22(1):249. PubMed ID: 38693584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Research progress in cuproptosis in liver cancer.
    Chen L; Liu D; Tan Y
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis.
    Guo J; Sun Y; Liu G
    J Inorg Biochem; 2023 Oct; 247():112324. PubMed ID: 37481825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copper homeostasis and cuproptosis in health and disease.
    Chen L; Min J; Wang F
    Signal Transduct Target Ther; 2022 Nov; 7(1):378. PubMed ID: 36414625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper homeostasis and cuproptosis in mitochondria.
    Tian Z; Jiang S; Zhou J; Zhang W
    Life Sci; 2023 Dec; 334():122223. PubMed ID: 38084674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Copper homeostasis and cuproptosis in gynecological disorders: Pathogenic insights and therapeutic implications.
    Lin Y; Yuan M; Wang G
    J Trace Elem Med Biol; 2024 Jul; 84():127436. PubMed ID: 38547725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Copper metabolism and cuproptosis in human malignancies: Unraveling the complex interplay for therapeutic insights.
    Abdullah KM; Kaushal JB; Takkar S; Sharma G; Alsafwani ZW; Pothuraju R; Batra SK; Siddiqui JA
    Heliyon; 2024 Mar; 10(5):e27496. PubMed ID: 38486750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper induces cell death by targeting lipoylated TCA cycle proteins.
    Tsvetkov P; Coy S; Petrova B; Dreishpoon M; Verma A; Abdusamad M; Rossen J; Joesch-Cohen L; Humeidi R; Spangler RD; Eaton JK; Frenkel E; Kocak M; Corsello SM; Lutsenko S; Kanarek N; Santagata S; Golub TR
    Science; 2022 Mar; 375(6586):1254-1261. PubMed ID: 35298263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cuproptosis: potential new direction in diabetes research and treatment.
    Qu J; Wang Y; Wang Q
    Front Endocrinol (Lausanne); 2024; 15():1344729. PubMed ID: 38904034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cuproptosis, the novel therapeutic mechanism for heart failure: a narrative review.
    Yuan HJ; Xue YT; Liu Y
    Cardiovasc Diagn Ther; 2022 Oct; 12(5):681-692. PubMed ID: 36329965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic changes during ovarian cancer progression as targets for sphingosine treatment.
    Anderson AS; Roberts PC; Frisard MI; McMillan RP; Brown TJ; Lawless MH; Hulver MW; Schmelz EM
    Exp Cell Res; 2013 Jun; 319(10):1431-42. PubMed ID: 23518387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting cuproplasia and cuproptosis in cancer.
    Tang D; Kroemer G; Kang R
    Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay of Ferroptosis and Cuproptosis in Cancer: Dissecting Metal-Driven Mechanisms for Therapeutic Potentials.
    Wang J; Li J; Liu J; Chan KY; Lee HS; Lin KN; Wang CC; Lau TS
    Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells.
    Kim KK; Lange TS; Singh RK; Brard L
    BMC Cancer; 2010 Feb; 10():72. PubMed ID: 20184758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.